ECSP22012347A - Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr - Google Patents

Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr

Info

Publication number
ECSP22012347A
ECSP22012347A ECSENADI202212347A ECDI202212347A ECSP22012347A EC SP22012347 A ECSP22012347 A EC SP22012347A EC SENADI202212347 A ECSENADI202212347 A EC SENADI202212347A EC DI202212347 A ECDI202212347 A EC DI202212347A EC SP22012347 A ECSP22012347 A EC SP22012347A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
alkyl
substituted
morpholinopyridine
derivatives
Prior art date
Application number
ECSENADI202212347A
Other languages
English (en)
Inventor
Paul Jones
Audrey Picard
Abbas Abdoli
Vouy Linh Truong
Cameron Black
Cyrus M Lacbay
Stéphanie Lanoix
Jean-François Truchon
Miguel St-Onge
Lee Fader
Stéphane Dorich
Sheldon N Crane
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2019/051539 external-priority patent/WO2020087170A1/en
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP22012347A publication Critical patent/ECSP22012347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos con la fórmula (I) o sales farmacéuticamente aceptables de estos, en donde - es un enlace simple, y cada Y es N o CR4; o - está ausente, y cada Y es NRY, carbonilo o (C(RY)2, en donde cada R1 es H o alquilo de C1-6 opcionalmente sustituido; R1 es alquilo de C1-6 opcionalmente sustituido o H; R3 es heteroarilo de C1-9 opcionalmente sustituido o alquilo de C1-6 heteroarilo de C1-9 opcionalmente sustituido; cada R4 es hidrógeno, halógeno, alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 opcionalmente sustituido o alquinilo de C2-6 opcionalmente sustituido; X es hidrógeno o halógeno; y R2 es como se define en la reivindicación 1. También se describen composiciones farmacéuticas que contienen los compuestos con la fórmula (I) y métodos para su preparación. Los compuestos con la fórmula (I) pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD-3 (ATR) y usarse para el tratamiento de enfermedades y afecciones tales como cánceres.
ECSENADI202212347A 2019-07-22 2022-02-16 Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr ECSP22012347A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877177P 2019-07-22 2019-07-22
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PCT/CA2020/051014 WO2021012049A1 (en) 2019-07-22 2020-07-22 Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors

Publications (1)

Publication Number Publication Date
ECSP22012347A true ECSP22012347A (es) 2022-03-31

Family

ID=74192632

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202212347A ECSP22012347A (es) 2019-07-22 2022-02-16 Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr

Country Status (14)

Country Link
US (1) US20220185809A1 (es)
EP (1) EP4003993A4 (es)
JP (1) JP2022541825A (es)
KR (1) KR20220035925A (es)
CN (1) CN114174292A (es)
AU (1) AU2020317381A1 (es)
BR (1) BR112022000431A2 (es)
CA (1) CA3148278A1 (es)
CO (1) CO2022001853A2 (es)
CR (1) CR20220068A (es)
EC (1) ECSP22012347A (es)
IL (1) IL289763A (es)
MX (1) MX2022000854A (es)
WO (1) WO2021012049A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072551A4 (en) * 2019-12-11 2023-11-15 Repare Therapeutics Inc. USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
WO2022226655A1 (en) * 2021-04-28 2022-11-03 Repare Therapeutics Inc. Methods of treating cancers having a biallelic loss of function or gene overexpression mutation
AU2022284632A1 (en) * 2021-06-04 2023-12-07 Repare Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
TW202321256A (zh) * 2021-07-27 2023-06-01 大陸商上海輝啟生物醫藥科技有限公司 ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途
CN113856764B (zh) * 2021-10-29 2022-11-01 华中科技大学 一种过渡金属催化剂及其制备方法和应用
CN116099390A (zh) * 2022-11-14 2023-05-12 石河子大学 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432225B (zh) * 2009-12-31 2019-02-19 和记黄埔医药（上海）有限公司 某些三唑并吡啶化合物和三唑并吡嗪化合物、其组合物和其使用方法
EP2566479B1 (en) * 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
EP2681216B1 (en) * 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2755962B1 (en) * 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US8906910B2 (en) * 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN107835814B (zh) * 2015-04-29 2021-07-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途
EP3402795B1 (en) * 2016-01-14 2019-10-30 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
WO2020087170A1 (en) * 2018-10-30 2020-05-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors

Also Published As

Publication number Publication date
IL289763A (en) 2022-03-01
MX2022000854A (es) 2022-02-10
CO2022001853A2 (es) 2022-03-29
CN114174292A (zh) 2022-03-11
EP4003993A1 (en) 2022-06-01
AU2020317381A1 (en) 2022-02-10
EP4003993A4 (en) 2023-01-18
CR20220068A (es) 2022-06-30
BR112022000431A2 (pt) 2022-03-03
CA3148278A1 (en) 2021-01-28
US20220185809A1 (en) 2022-06-16
KR20220035925A (ko) 2022-03-22
WO2021012049A1 (en) 2021-01-28
JP2022541825A (ja) 2022-09-27
WO2021012049A8 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
ECSP22012347A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
UY26968A1 (es) Agentes terapéuticos
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
CL2012001699A1 (es) Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras.
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
AR040580A1 (es) Derivados de pirazol heterobiciclico como inhibidores de la quinasa
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок